Caffeine Tablets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Drop these in your water to stay extra hydrated on the go.

Granules India rose 1.57% to Rs 326.90 after the company said that US drug regulator has approved its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).The product is bioequivalent to the reference listed drug product (RLD), Excedrin migraine tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The drug is indicated for treating migraine. The product will be manufactured at the company's Hyderabad facility and is expected to be launched shortly. Priyanka Chigurupati, Executive Director, Granules Pharmaceuti...

Read more about Sensex above 50,000 mark; breadth strong on Business Standard. The S&P BSE Sensex was trading firm in afternoon trade. The index once again crossed the 50,000 mark. Trading has been halted on the National Stock Exchange (NSE) due to technical glitches.

The U.S. Food and Drug Administration has approved Granules India’s Abbreviated New Drug Application for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).The company said the

Granules India Limited announces approval of Acetaminophen, Aspirin and Caffeine Tablets (OTC) Posted On: 2021-02-24 00:20:48 (Time Zone: Arizona, USA) Granules India Limited announced today that the US Food & Drug Administration (US FDA) has approved its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC). It is bioequivalent to the reference listed drug product (RLD), Excedrin Migraine Tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The product would be manufactured at our Hyderabad facility and is...